Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Towards a chlamydia vaccine

Chlamydia is the most common sexually transmitted bacterial infection in humans but is often asymptomatic. Left untreated, chlamydia infection can lead to serious complications, such as infertility, and thus vaccine development is a priority. Morrison et al. studied Chlamydia muridarum infection in mice, isolating a mutant C. muridarum strain (termed GIAM-1) that shows substantially reduced infection of the genital tract compared with that of the wild type. However, GIAM-1 efficiently infected the gastrointestinal tract, which induced robust humoral immunity against C. muridarum. Importantly, gastrointestinal tract infection with GIAM-1 protected mice against subsequent genital tract infection with wild-type C. muridarum. These results suggest that by manipulating tissue-tropism to obtain immunogenic bacterial strains that do not infect the genital tract, a live-attenuated vaccine for the human pathogen Chlamydia trachomatis might be obtainable.


Original article

  1. Morrison, S. G. et al. A genital infection-attenuated Chlamydia muridarum mutant infects the gastrointestinal tract and protects against genital tract challenge. mBio 11, e02770-20 (2020)

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Grant Otto.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Otto, G. Towards a chlamydia vaccine. Nat Rev Microbiol 19, 3 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing